RA Capital Management, a multi-stage investment manager, led a $220m Series C funding round in Exo, a medical device startup. The round was joined by BlackRock, Sands Capital, Avidity Partners and Pura Vida Investments. “It is clear to us that ultrasound is the future — it is nonradiating and has no harmful side effects. We want to take the technology and put it in the palms of physicians. We also want to bring it down to the patient level. The beauty of having this window into the body is you can immediately see things,” Sandeep Akkaraju, Exo CEO.